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ORIGINAL ARTICLE
Treatment of Rheumatoid Arthritis With
Anti–Tumor Necrosis Factor or Tocilizumab
Therapy as First Biologic Agent in a Global
Comparative Observational Study
ERNEST H. CHOY,1 CORRADO BERNASCONI,2 MAHER AASSI,2 JOSE FERNANDO MOLINA,3 AND
OSCAR MASSIMILIANO EPIS4
Objective. To compare clinical effectiveness between tocilizumab and tumor necrosis factor inhibitors (TNFi) in patients
with rheumatoid arthritis (RA) and inadequate response to conventional synthetic disease-modifying antirheumatic drugs ini-
tiating biologic therapy.
Methods. Patients prescribed tocilizumab (intravenous) or TNFi were prospectively observed in routine clinical practice for
52 weeks across 158 sites in 26 countries. The primary observation was the change from baseline in Disease Activity Score
based on 28 joints using the erythrocyte sedimentation rate (DAS28-ESR) at week 24 using analysis of covariance for between-
groups comparison. Secondary end points included Clinical Disease Activity Index (CDAI) and patient-reported outcomes at
weeks 24 and 52.
Results. Of 1,216 patients, 35% initiated tocilizumab and 65% initiated TNFi. RA duration was shorter, and disease activity
and corticosteroid use were higher in tocilizumab patients. Tocilizumab-treated patients had greater improvement in DAS28-
ESR at weeks 24 and 52 (week 24 difference [95% confidence interval] in adjusted means:20.831 [21.086,20.576]; P< 0.001).
Change from baseline in CDAI was also greater with tocilizumab (adjusted means difference: week 24,23.48; week 52,24.60;
both P<0.001). Tocilizumab-treated patients had more improvement in the Health Assessment Questionnaire disability index
than TNFi-treated patients (P<0.05). The cumulative probability of drug discontinuation at week 52 was lower with
tocilizumab (15%) than TNFi (27%; P<0.001, unadjusted analysis). Unadjusted frequencies (events per 100 patient-years) for
tocilizumab and TNFi were 6.44 and 11.99 for serious adverse events, 1.98 and 5.03 for serious infections, and 0.74 and 0.77
for deaths, respectively.
Conclusion. Patients initiating tocilizumab experienced greater effectiveness and drug survival than those initiating TNFi in
an observational setting.
INTRODUCTION
Current American College of Rheumatology (ACR) and Euro-
pean League Against Rheumatism guidelines recommend
initiating treatment with biologic disease-modifying
antirheumatic drugs (DMARDs) in patients with rheumatoid
arthritis (RA) who have not responded to conventional syn-
thetic DMARDs (csDMARDs) or who have high disease
activity and features of poor prognosis (1,2). Many biologic
agents are available for the treatment of RA; tumor necrosis
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factor inhibitors (TNFi), abatacept, and the interleukin-6 (IL-
6) receptor a inhibitor tocilizumab are recommended; under
certain circumstances, rituximab may be used (2). However,
evidence is lacking regarding which biologic agents should
be used and in what sequence.
Only a few head-to-head clinical trials comparing biologic
agents in patients with RA have been conducted to date. The
randomized controlled phase IV ADACTA trial in patients
with RA who were intolerant of methotrexate or for whom
continued therapy with methotrexate was inappropriate
demonstrated superiority of tocilizumab monotherapy over
adalimumab monotherapy for change in the Disease Activity
Score in 28 joints using the erythrocyte sedimentation rate
(DAS28-ESR) from baseline to week 24. More tocilizumab-
treated than adalimumab-treated patients achieved remission
according to the DAS28-ESR (DAS28 ,2.6) and the Clinical
Disease Activity Index (CDAI #2.8) (3). The phase IIIb
AMPLE (Abatacept versus Adalimumab Comparison in
Biologic-Naive RA Subjects with Background Methotrexate)
trial demonstrated similar clinical efficacy and inhibition of
radiographic progression between abatacept and adalimu-
mab in combination with methotrexate in patients with RA
who had an inadequate response to methotrexate (4). Rituxi-
mab was noninferior to TNFi treatment for change in the
DAS28-ESR in the open-label ORBIT (Optimal Management
of RA Patients Who Require Biologic Therapy) trial in
patients with RA who had an inadequate response to
csDMARDs (5). Comparison of effectiveness and drug sur-
vival between tocilizumab and TNFi in RA is limited to indi-
rect comparison of clinical trial data and small observational
studies (6–9).
The current study (ACT-iON) is the first prospective, large-
scale, global, multicenter, comparative effectiveness study
comparing initiation of intravenous tocilizumab with initia-
tion of a TNFi in patients with RA as the first-line biologic
agent treatment after an inadequate response to csDMARDs
in a real-world, clinical practice setting. Biologic therapy
may be initiated in combination with csDMARDs or as mono-
therapy in clinical practice according to the decision of the
treating physician; this study provides an opportunity to
compare tocilizumab and TNFi therapy in combination with
csDMARDs.
PATIENTS AND METHODS
Study design. ACT-iON was conducted at 158 sites in 26
countries (ClinicalTrials.gov: NCT01543503). Clinical effec-
tiveness and safety outcomes of TNFi and tocilizumab were
observed for 52 weeks of routine clinical practice after the
initiation of the first biologic-agent therapy for the treatment
of patients with RA. The study was observational; no addi-
tional diagnostic or therapeutic procedures were performed
beyond routine clinical practice.
Patients. The study included adult patients with moder-
ate to severe RA, defined according to 1987 ACR criteria (10),
of at least 24 weeks’ duration who were nonresponders or
who were intolerant of csDMARD therapy and whose
treating physicians decided to initiate treatment with a TNFi
or with intravenous tocilizumab in accordance with the local
label (tocilizumab was initiated at 8 mg/kg in all patients
because the study was not conducted in the US or Canada,
where the starting dose is 4 mg/kg [11,12]) as their first bio-
logic agent. The study was conducted in compliance with
the Declaration of Helsinki and Good Clinical Practice and
with the institutional review board/ethics committee.
Patients provided written informed consent.
Assessments. Data were collected between February 9,
2012 and February 20, 2015. Patients might have initiated
treatment before study start because the enrollment visit
could occur up to 6 weeks after initiation of the first biologic
agent. The primary observation was the mean change from
baseline in the DAS28-ESR at week 24. Secondary outcome
measures included mean change from baseline in the
DAS28-ESR at week 52, swollen joint count (SJC), tender
joint count (TJC), remission rates according to the DAS28-
ESR and CDAI, and patient-reported outcomes, including
the Health Assessment Questionnaire disability index (HAQ
DI). Safety was assessed throughout the study by monitoring
adverse events (AEs), serious AEs (SAEs), abnormalities in
laboratory assessments, and vital signs.
Statistical analysis. The initial target sample size was
2,000 patients, which was expected to provide 90% power to
detect a between-groups difference of 0.3 DAS28 units. How-
ever, a slower than anticipated recruitment rate resulted in a
final sample size of 1,225 patients, which was expected to pro-
vide a detectable difference of approximately 0.4 DAS28 units.
Safety was assessed in the safety population (all patients who
received$1 dose of a TNFi or tocilizumab). The primary effec-
tiveness analysis population included all patients in the safety
population administered their first biologic agent within 60
days after the previous RA disease activity measurement.
Missing values were not imputed for the primary analyses.
Significance was determined as a P value less than 0.05 with-
out correction for multiple testing. Differences in baseline
characteristics were assessed using the Wilcoxon rank sum
test or chi-square test. Estimation of the primary outcome in
the 2 treatment groups was based on an analysis of
Significance & Innovations
 To date, comparative efficacy of the interleukin-6
receptor a monoclonal antibody tocilizumab (TCZ)
and tumor necrosis factor inhibitors (TNFi) for the
treatment of rheumatoid arthritis has been investi-
gated in a single head-to-head trial of TCZ mono-
therapy versus adalimumab monotherapy and
network meta-analyses.
 This prospective, observational, comparative effec-
tiveness study provides the first real-world evi-
dence of effectiveness and persistence on
treatment for patients who initiated TCZ compared
with those who initiated TNFi in routine clinical
practice, as measured by the Disease Activity
Score in 28 joints using the erythrocyte sedimenta-
tion rate and the Clinical Disease Activity Index.
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covariance (ANCOVA) model that included baseline
DAS28-ESR as a covariate and concomitant csDMARDs and
country as factors. Given the selection and channeling bias
possible in observational studies (13,14), supportive analy-
ses were performed for DAS28-ESR and CDAI change from
baseline to week 24 using matched-pair analysis based on
the propensity score. This was computed using multiple
logistic regression based on all relevant and evaluable base-
line covariates (see Supplementary Table 1, available on the
Arthritis Care & Research web site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.23303/abstract). Post hoc sensi-
tivity analyses were performed on the primary end point
using any type of DAS28 to account for missing DAS28-ESR
values. Data were restricted to patients with baseline disease
activity assessments within 0–14 days before their first bio-
logic agent treatment and used multiple imputation of miss-
ing week 24 DAS28-ESR values in the same ANCOVA
model as that for the primary analysis. Additional post hoc
sensitivity analyses included adjustment for age, disease
duration, seropositivity, steroid use at baseline, history of
malignant tumor, and treatment in the ANCOVA model.
Models similar to those for the primary analysis were used to
analyze other end points, such as CDAI and joint counts.
Chi-square analysis was used for between-groups compari-
sons of the proportion of patients in DAS28 remission and
other categorical variables. Drug survival was analyzed
Table 1. Baseline demographics and treatments (safety population–all patients)*
TCZ
(n5423)
TNFi
(n5 793) P
Age, mean6SD years 54.36 12.8 55.2613.1 0.171†
Disease duration, mean6SD years 7.86 7.3 9.469.0 0.014†
DAS28-ESR, mean6SD‡ 5.86 1.1§ 5.561.2¶ 0.030†
SJC, mean6SD‡ 9.06 6.2# 7.46 5.3** , 0.001†
TJC, mean6SD‡ 12.1 66.9†† 12.167.6** 0.688†
CDAI, mean6SD‡ 33.0 6 13.5‡‡ 31.26 13.2§§ 0.077†
HAQ DI, mean6SD‡ 1.5 (0.7)§ 1.5 (0.7)¶¶ 0.968†
Initiated biologic agent as monotherapy, no. (%) 119 (28.1) 127 (16.0) , 0.001##
Initiated biologic agent in combination with
csDMARDs, no. (%)
312 (73.8) 679 (85.6) –
MTX, no. (%) [median dose, mg/week]*** 233 (74.7) [15.0] 541 (79.7) [15.0] –
Hydroxychloroquine, no. (%)††† 70 (22.4) 179 (26.4) –
Leflunomide, no. (%)††† 73 (23.4) 124 (18.3) –
Sulfasalazine, no. (%)††† 37 (11.9) 122 (18.0) –
Oral corticosteroid use, no. (%)‡‡‡ 256 (60.5) 369 (46.5) , 0.001##
Oral corticosteroid dose, mean6SD mg/day‡‡‡ 8.3 (5.55)§§§ 7.3 (5.31)§§ –
History of comorbid conditions, no. (%)
Other autoimmune disease 32 (7.6) 41 (5.2) 0.205¶¶¶
Overlap syndrome 10 (2.4) 12 (1.5) 0.060¶¶¶
Chronic hepatic impairment 11 (2.6) 27 (3.4) 0.774¶¶¶
Severe and/or progressive infection 12 (2.8) 22 (2.8) 0.709¶¶¶
Central nervous system demyelination 5 (1.2) 3 (0.4) 0.178¶¶¶
Severe immunosuppression 0 (0.0) 2 (0.3) 0.518¶¶¶
Malignant tumor 20 (4.7) 12 (1.5) 0.005¶¶¶
Lymphoproliferative syndrome 1 (0.2) 0 (0.0) 0.016¶¶¶
Angina/other heart disease 51 (12.1) 120 (15.1) 0.327¶¶¶
Other clinically significant comorbidities 258 (61.0) 512 (64.6) 0.451¶¶¶
* TCZ5 tocilizumab; TNFi5 tumor necrosis factor inhibitor; DAS28-ESR5Disease Activity Score in 28 joints
using the erythrocyte sedimentation rate; SJC5 swollen joint count; TJC5 tender joint count; CDAI5Clinical
Disease Activity Index; HAQ DI5Health Assessment Questionnaire disability index; csDMARDs5 conventional
synthetic disease-modifying antirheumatic drugs; MTX5methotrexate.
† Based on Wilcoxon’s rank sum test.
‡ Primary effectiveness population.
§ N5 230.
¶ N5 402.
# N5 352.
** N5 621.
†† N5 353.
‡‡ N5 238.
§§ N5 358.
¶¶ N5 408.
## Based on chi-square test for comparison of monotherapy and combination therapy between both treatment
groups.
*** Percentages based on number of patients who initiated a biologic agent in combination with csDMARDs.
For MTX dose: TCZ, n5 233; TNFi, n5538.
††† Percentages based on number of patients who initiated biologic agent in combination with csDMARDs.
‡‡‡ Prednisone equivalent.
§§§ N5248.
¶¶¶ Based on Fisher’s exact test.
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according to the Kaplan-Meier method, and between-groups
comparisons were performed based on the log rank test.
RESULTS
Patient disposition. In total, 1,216 patients initiated
tocilizumab or TNFi therapy as their first biologic agent.
Tocilizumab was initiated in 423 patients (35%) and TNFi in
793 patients (65%). The safety population was composed of
the same 423 patients treated with tocilizumab and 793
patients treated with TNFi. The primary effectiveness popula-
tion included 390 patients treated with tocilizumab and 693
patients treated with TNFi (see Supplementary Figure 1 and
Supplementary Table 2, available on the Arthritis Care &
Research web site at http://onlinelibrary.wiley.com/doi/10.
1002/acr.23303/abstract). Of the TNFi-treated patients, 315
(39.7%) received etanercept, 203 (25.6%) received adalimu-
mab, 155 (19.5%) received certolizumab pegol, 65 (8.2%)
received infliximab, and 55 (6.9%) received golimumab.
Excluding 21 screen failures, 162 patients (13.3%) withdrew
from the study overall: 75 (17.7%) among patients who initi-
ated tocilizumab as a first biologic drug and 87 (11.0%) among
patients who initiated TNFi. The most common reason was
loss to followup, which occurred for 32 tocilizumab-treated
patients (7.6%) and 36 TNFi-treated patients (4.5%). Nine
tocilizumab-treated patients (2.1%) and 13 TNFi-treated
patients (1.6%) withdrew because of AEs, 4 tocilizumab-
treated (0.9%) and 16 TNFi-treated patients (2.0%) withdrew
because of lack of efficacy, and 8 tocilizumab-treated (1.9%)
and 10 TNFi-treated patients (1.3%) withdrew consent. Over-
all, 34 patients (2.8%) withdrew for other reasons; 22 (5.2%)
of them received tocilizumab and 12 (1.5%) received TNFi.
Tocilizumab was initiated more often than TNFi as monother-
apy (28.1% versus 16.0%;P, 0.001) (Table 1).
Baseline characteristics. Baseline demographics, disease
characteristics, and concomitant therapies were only partially
similar between the groups. Patients initiating tocilizumab
had shorter mean6SD disease duration than patients who
initiated TNFi (7.867.3 years versus 9.46 9.0 years;
P5 0.014). They also had a slightly higher mean6SD
DAS28-ESR (5.861.1 versus 5.56 1.2; P50.030) and SJC
(9.06 6.2 versus 7.465.3; P,0.001) and more frequent oral
corticosteroid use (60.5% versus 46.5%; P,0.001) than
patients who started TNFi. Among combination therapy
patients, the most common concomitant csDMARD at base-
line was methotrexate (74.7% for tocilizumab-treated patients
and 79.7% for TNFi-treated patients); in both groups, the
median dosage was 15 mg/week (Table 1). Additional base-
line characteristics are shown in Supplementary Table 3,
available on the Arthritis Care & Research web site at http://
onlinelibrary.wiley.com/doi/10.1002/acr.23303/abstract.
Significant effects associated with the treatment choice
were country (UK and Spain were countries with clearly
larger proportions of patients receiving TNFi), and intoler-
ance was a reason for stopping the previous csDMARD
(favoring the choice of tocilizumab: odds ratio [OR] 0.59
[95% confidence interval (95% CI) 0.42, 0.82], P50.002)
and current alcohol intake (favoring TNFi: OR 1.83 [95% CI
1.16, 2.88], P5 0.0092) (see Supplementary Table 1, avail-
able on the Arthritis Care & Research web site at http://
onlinelibrary.wiley.com/doi/10.1002/acr.23303/abstract).
Effectiveness. Patients who received tocilizumab as their
first biologic agent had significantly more change from base-
line in DAS28-ESR to week 24 (primary end point) and week
Figure 1. Adjusted mean change from baseline to weeks 24 (primary end point) and 52
in the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate
(DAS28-ESR; primary effectiveness population–all patients). Analyses were based on
analysis of covariance models, with changes from baseline in DAS28-ESR at week 24
or 52 as dependent variables, country (week 24 analysis) and treatment as fixed effects,
and DAS28-ESR at baseline as a covariate. 95% CI5 95% confidence interval;
TCZ5 tocilizumab; TNFi5 tumor necrosis factor inhibitor.
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52 than those who initiated TNFi (treatment difference [95%
CI] for week 24: 20.831 [21.086, 20.575] and for week 52:
20.910 [21.204, 20.617], both P, 0.001) (Figure 1). Results
of the primary effectiveness analysis were confirmed by sen-
sitivity analyses (see Supplementary Table 4, available on the
Arthritis Care & Research web site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.23303/abstract). Sensitivity ana-
lysis of change from baseline in any type of DAS28 (calcu-
lated using ESR, or C-reactive protein [CRP] if ESR was not
available, and using DAS28 values entered by the investiga-
tor without each component), analysis of any type of DAS28
restricted to patients who had baseline disease activity
assessments no longer than 2 weeks before their first biologic
agent treatment, and a model making use of multiple imputa-
tion confirmed the primary effectiveness results; ANCOVA
accounting additionally for seropositivity, age, disease dura-
tion, steroid use at baseline, history of malignant tumor, and
treatment, as well as propensity score matching, also resulted
in a significantly more change from baseline in DAS28-ESR
to week 24 (see Supplementary Tables 1 and 4, available on
theArthritis Care & Researchweb site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.23303/abstract). The smallest
between-groups treatment difference in all these supportive
analyses was 20.748. The mean6SD treatment difference
for the propensity score–based matched-pair analysis for
DAS28-ESR was 21.0562.07; P, 0.001. Low patient num-
bers precluded viable effectiveness analysis of the data by
monotherapy versus combination therapy with csDMARDs;
only 28 patients treated with tocilizumab monotherapy and
42 treated with TNFi monotherapy were evaluable for the
primary effectiveness analysis. Analysis showed that among
monotherapy patients, however, the treatment difference
(95% CI) was not statistically significant for change from
baseline in DAS28-ESR at week 24 or 52; monotherapy
20.287 (21.194, 0.621; P5 0.530) at week 24 and 20.598
(21.289, 0.093; P5 0.089) at week 52, and combination ther-
apy 20.950 (21.220, 20.680; P, 0.001) at week 24 and
20.972 (21.297, 0.647; P, 0.001) at week 52 (see Supple-
mentary Table 5, available on the Arthritis Care & Research
web site at http://onlinelibrary.wiley.com/doi/10.1002/acr.
23303/abstract).
Statistically significantly greater decreases from baseline
to week 24 for patients who initiated tocilizumab compared
with those who initiated TNFi were observed for ESR, CRP,
and SJC (treatment differences [95% CI]: 213.23 [215.51,
210.95], 26.67 [10.27, 3.07], and 20.58 [21.08, 20.08]; all
P,0.05) (Table 2). There was no statistically significant dif-
ference in TJC between the treatment groups at week 24 in
the primary models. At week 52, the treatment difference
was significant for ESR (212.65 [215.42, 29.88]; P, 0.001),
SJC (20.75 [21.24, 20.27]; P5 0.002), and TJC (21.22
[22.04,20.39]; P50.004), but not for CRP.
Decreases in CDAI and Simplified Disease Activity Index
(SDAI) from baseline to weeks 24 and 52 were also signifi-
cantly greater in patients who initiated tocilizumab treat-
ment than in those who initiated TNFi treatment (treatment
differences [95% CI]: CDAI: 23.48 [25.48, 21.47] at week
24 and 24.60 [26.71, 2.49] at week 52; SDAI: 23.23 [25.81,
20.65] at week 24 and 23.25 [26.12, 20.37] at week 52; all
P,0.05). Significantly higher proportions of tocilizumab-
Figure 2. Proportions of patients achieving remission at weeks 24 and 52 according to
the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate
(DAS28-ESR), the Clinical Disease Activity Index (CDAI), and the Simplified Disease
Activity Index (SDAI) criteria (primary effectiveness population–all patients; unad-
justed analysis). *5P, 0.001 and † 5 P,0.05 for tocilizumab (TCZ) vs. tumor necro-
sis factor inhibitor (TNFi; chi-square test).
Comparative Effectiveness of Tocilizumab and TNF Inhibitors in RA 1489
treated than TNFi-treated patients were in remission at week
24 according to DAS28-ESR (44.7% versus 29.7%;
P, 0.001) and CDAI (22.4% versus 14.6%; P5 0.015), but
not SDAI (21.3% versus 15.7%; P50.152). By week 52, sig-
nificantly higher proportions of tocilizumab-treated than
TNFi-treated patients had achieved remission according to
all 3 measures (Figure 2). Propensity score (calculated using
logistic regression analysis with treatment group as the
dependent variable and baseline factors as covariates)
matched-pair analysis produced results comparable to those
of the primary ANCOVA analysis of mean change from base-
line to week 24 in CDAI (mean6SD treatment difference
23.22620.29; P50.0480) (see Supplementary Table 6, avail-
able on the Arthritis Care & Research web site at http://
onlinelibrary.wiley.com/doi/10.1002/acr.23303/abstract).
There was a significant difference in improvement in
patient-reported outcomes between patients who received
tocilizumab and those who received TNFi as their first bio-
logic agent, as demonstrated by a significantly greater
decrease in HAQ DI and Functional Assessment of Chronic
Illness Therapy fatigue scores at week 24 (Table 2).
Drug survival. Termination of initial biologic therapy
was reported for 14.9% of patients who started tocilizumab
and 27.4% of those who started TNFi; of these patients,
38.1% and 40.1%, respectively, terminated because of
AEs and 23.8% and 48.8%, respectively, terminated
because of lack of efficacy. It should be noted that
patients could terminate their biologic-agent therapy but
remain in the study or could withdraw from the study
without terminating their biologic therapy. Drug survival
analysis, in which observations for patients who com-
pleted the study on the initial biologic therapy and those
who withdrew prematurely from the study without a
biologic-agent discontinuation (e.g., patients lost to fol-
lowup) were censored, showed that drug survival was
significantly higher with tocilizumab than with TNFi
(P,0.001) (Figure 3). The probability of tocilizumab
discontinuation was 9% (95% CI 6%, 12%) by week 24
and 15% (95% CI 12%, 19%) by week 52. The cumula-
tive probability of TNFi discontinuation was 15% (95%
CI 13%, 18%) at week 24 and 27% (95% CI 24%, 30%)
by week 52.
Safety. AEs and SAEs were reported in similar propor-
tions and at similar rates per 100 patient-years in patients
who started tocilizumab and patients who started TNFi
(Table 3). Infections and infestations were the most com-
mon AEs and SAEs in both groups; serious infections
were reported in 8 (1.9% [8 events; 1.98 per 100 patient-
years]) tocilizumab-treated patients and 26 (3.3% [39
events; 5.03 per 100 patient-years]) TNFi-treated patients
(lower respiratory tract infection in 6 TNFi-treated
patients and no tocilizumab-treated patients, pneumonia
in 6 TNFi-treated patients and 2 tocilizumab-treated
patients). Three patients in the tocilizumab group died (2
of pneumonia, 1 of cardiac failure), and 6 patients in the
TNFi group died (1 of fecal peritonitis and multiorgan
failure; 1 of surgical graft infection and 1 of sepsis; 1 of
metastatic neoplasm and cerebrovascular accident; 1 of
sepsis; 1 of metastatic neoplasm; and 1 of pneumonia
and pericardial effusion). Two deaths from pneumonia (1
in each group) were deemed related to treatment,
according to the investigator. Further details of the
deaths can be found in Supplementary Table 7, available
on the Arthritis Care & Research web site at http://
onlinelibrary.wiley.com/doi/10.1002/acr.23303/abstract.
Numeric differences were observed in the incidence of
patients experiencing shifts in neutrophil counts, liver
transaminase levels, or lipid profile parameters from nor-
mal at baseline to abnormal at week 24 or 52 between the
treatment groups, but no difference was seen between
weeks 24 and 52 for the individual treatment groups
(Supplementary Table 8, available on the Arthritis Care
& Research web site at http://onlinelibrary.wiley.com/
doi/10.1002/acr.23303/abstract).
Figure 3. Drug survival on tocilizumab (TCZ) and tumor necrosis factor inhibitor
(TNFi) (safety population–all patients; unadjusted analysis) based on Kaplan-Meier
curve of time to discontinuation of biologic agent therapy. Patients for whom a biologic
agent was not discontinued were censored at the study day of termination. P values
were based on log rank test.
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DISCUSSION
This is the first large-scale, multinational, prospective study
to present real-life data on the use and drug survival of first-
line intravenous tocilizumab and TNFi initiated in RA
patients with an inadequate response to csDMARDs.
Reflecting the observational nature of the study, there were
no predefined interventions; the decision to initiate
tocilizumab or TNFi was not based on protocol but on a deci-
sion made between the physician and the patient.
Significantly greater improvement in the DAS28-ESR was
seen at weeks 24 (primary end point) and 52 for patients
who initiated tocilizumab as their first-line biologic agent
compared with those who initiated TNFi. Since neither phy-
sicians nor patients were blinded to ESR or CRP results,
there is a potential bias for overestimation of the effective-
ness of tocilizumab influenced by changes in these markers
of inflammation. Significantly greater improvement in CDAI
was also observed for the tocilizumab group compared with
the TNFi group. Calculation of the CDAI does not include
the acute-phase reactants CRP or ESR, suggesting that
DAS28 results were not solely influenced by the effect of
inhibition of IL-6 signaling with tocilizumab on acute-phase
reactants. Significantly higher proportions of tocilizumab-
Table 3. Safety (safety population)*
TCZ
(n5423)
TNFi
(n5793)
Total
(n5 1,216)
Exposure, no. patient-years 403.7 775.8 1179.5
AEs, no. (%) 208 (49.2) 449 (56.6) 657 (54.0)
Events, no. 501 1,011 1,512
Events, no. per 100 patient-years 124.10 130.32 128.19
AEs leading to withdrawal, no. (%) 9 (2.1) 13 (1.6) 22 (1.8)
Events, no. 9 19 28
Events, no. per 100 patient-years 2.23 2.45 2.37
AEs of special interest, no. (%) 34 (8.0) 42 (5.3) 76 (6.3)
Infections, no. (%) 88 (20.8) 205 (25.9) 293 (24.1)
SAEs, no. (%) 22 (5.2) 64 (8.1) 86 (7.1)
Events, no. 26 93 119
Events, no. per 100 patient-years 6.44 11.99 10.09
Serious infections, no. (%) 8 (1.9) 26 (3.3) 34 (2.8)
Events, no. 8 39 47
Events, no. per 100 patient-years 1.98 5.03 3.98
Deaths, no. (%) 3 (0.7) 6 (0.8) 9 (0.7)
Events, no. per 100 patient-years 0.74 0.77 0.76
AEs of special interest SOC and preferred term, no. (%)†
Gastrointestinal disorders 0 3 (0.4) 3 (0.2)
Upper gastrointestinal hemorrhage 0 2 (0.3) 2 (0.2)
General disorders and administration site conditions 1 (0.2) 4 (0.5) 5 (0.4)
Injection site reaction 0 2 (0.3) 2 (0.2)
Immune system disorders 3 (0.7) 4 (0.5) 7 (0.6)
Hypersensitivity 2 (0.5) 3 (0.5) 5 (0.4)
Infections and infestations 9 (2.1) 20 (2.5) 29 (2.4)
Gastroenteritis 0 2 (0.3) 2 (0.2)
Lower respiratory tract infection 0 3 (0.4) 3 (0.2)
Pneumonia 2 (0.5) 6 (0.8) 8 (0.7)
Urinary tract infection 0 2 (0.3) 2 (0.2)
Injury, poisoning, and procedural complications 2 (0.5) 1 (0.1) 3 (0.2)
Infusion-related reaction 2 (0.5) 0 2 (0.2)
Investigations 6 (1.4) 2 (0.3) 8 (0.7)
ALT increased 2 (0.5) 0 2 (0.2)
Transaminases increased 4 (0.9) 1 (0.1) 5 (0.4)
Neoplasms benign, malignant, and unspecified
(including cysts and polyps)
2 (0.5) 3 (0.4) 5 (0.4)
Metastatic neoplasm 0 2 (0.3) 2 (0.2)
Nervous system disorders 2 (0.5) 4 (0.5) 6 (0.5)
Cerebrovascular accident 0 2 (0.3) 2 (0.2)
Skin and subcutaneous tissue disorders 9 (2.1) 3 (0.4) 12 (1.0)
Dermatitis allergic 0 2 (0.3) 2 (0.2)
Rash 6 (1.4) 0 6 (0.5)
* TCZ5 tocilizumab; TNFi5 tumor necrosis factor inhibitor; AEs5 adverse events; SAEs5 serious AEs;
SOC5 system organ class; ALT5 alanine aminotransferase.
† AEs reported in .1 patient in either treatment group.
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treated patients than TNFi-treated patients achieved remis-
sion according to CDAI criteria (CDAI#2.8) at weeks 24 and
52, but it should be noted that for SDAI remission (SDAI
#3.3), which does include calculation of CRP, the difference
between tocilizumab and TNFi was significant only at week
52. Data on physical function, pain, and fatigue, though
sometimes available in a minority of patients, were also con-
sistent with the observation of greater effectiveness of
tocilizumab. Tocilizumab was initiated as monotherapy
more often than TNFi; however, the small number of
patients in the primary effectiveness population prevented
meaningful analysis of its effectiveness as monotherapy
compared with combination therapy. The effectiveness of
tocilizumab monotherapy compared with TNFi monother-
apy should be investigated in a larger patient cohort.
Comparison between results of the current study and the
published literature should account for differences in patient
populations, study designs, and patterns and durations of
treatment. Nevertheless, effectiveness results observed with
tocilizumab in reports from clinical practice support the
results of our study. For example, in ACT-SURE, an open-
label study of csDMARD-inadequate responders treated with
tocilizumab in clinical practice (15), 6-month CDAI and
SDAI remission rates were 21.1% and 24.2%, respectively.
In the current study, they were 22.4% and 21.3%, respec-
tively. DAS28 remission rates in ACT-SURE (61.6%) were
higher than in the current study (44.7%). Effectiveness data
for TNFi agents are available from national registry data-
bases. In the Consortium of Rheumatology Researchers of
North America (CORRONA) registry, RA patients who
started treatment with TNFi had a DAS28-ESR remission
rate of 29.3% and a CDAI remission rate of 16.2% after 12
months (16). In the US Veterans Affairs Rheumatoid Arthri-
tis (VARA) registry, the mean change from baseline in
DAS28 after initiation of TNFi ranged from 20.77 to 21.20
(17), which is consistent with the mean change in the current
study. The CORRONA and VARA registries collect data
from patients in the US, whereas the current study did not
include US patients. ADACTA is the only head-to-head trial
to date comparing tocilizumab with a TNFi (adalimumab); it
demonstrated the superior improvement in DAS28-ESR over
6 months with tocilizumab. Network meta-analyses of ran-
domized controlled trial data have also been performed to
investigate relative efficacies of biologic therapies in patients
with RA. Comparable ACR response rates have been found
between tocilizumab and TNFi agents in combination with
DMARDs (18–20). DAS28 remission rates may be higher for
tocilizumab than for abatacept, but this could be a result of
the direct effect of tocilizumab on CRP levels (18). These net-
work meta-analysis results are in contrast to the results of
the current study, which showed better effectiveness for
tocilizumab than TNFi (primarily in combination with
DMARDs) as measured by DAS28-ESR and CDAI. Given the
conflicting results between the literature and the current
study and the limitations of comparing studies with different
trial designs in network meta-analyses, prospective random-
ized trials are needed before robust conclusions can be
drawn.
Patients who initiated tocilizumab in the current study
had higher drug survival rates than those who initiated
TNFi, which may be related to differences observed in
clinical effectiveness. The proportion of patients who
remained on tocilizumab during this study (85.1%) is con-
sistent with previously reported 6-month tocilizumab sur-
vival rates in clinical practice in the ACT-UP study (82.7%)
(21). Similarly, the proportion of patients who remained on
TNFi (72.6%) was consistent with the proportion reported
in the CORRONA registry after 12 months of TNFi therapy
(72%) (16). Comparison in an Australian health care data-
base of biologic agents for the treatment of RA suggested that
patients may be more persistent with tocilizumab and abata-
cept initiated as the first biologic-agent therapy than with
subcutaneous TNFi agents. Combination therapy with meth-
otrexate improved persistence with abatacept and subcuta-
neous TNFi but not with tocilizumab (22).
The safety profiles of tocilizumab and TNFi were compara-
ble to the safety profiles reported in clinical trials and clini-
cal practice (15,21,23–28). A recent Japanese prospective
cohort study (29) comparing the safety of tocilizumab and
TNFi in clinical practice reported that the risks for SAEs and
serious infections were not significantly different during the
first year of treatment when adjusted for baseline covariates.
Results of this study should be interpreted with an under-
standing of the limitation of potential biases associated with
observational studies, including channeling bias. Confound-
ing was addressed in a set of analyses adjusting for potential
response predictors, including propensity score–based
matching. All these analyses supported the key findings of
the study. Results of the propensity score–based matched-
pair analyses were comparable to those of the primary analy-
sis for both DAS28-ESR and CDAI. Among other limitations
were the amount of missing data for the effectiveness analy-
sis (likely because of the observational nature of the study),
the fact that DAS28-ESR was not used systematically in all
centers (some centers used CRP for the calculation of
DAS28), and the fact that delayed initiation of a prescribed
treatment might have contributed to the lack of data for some
baseline variables. Nevertheless, supportive efficacy analy-
ses using end points with fewer missing values, including
DAS28-CRP and using imputation of missing data, provided
comparable results.
In conclusion, patients in the ACT-iON observational
study who initiated tocilizumab as their first biologic-agent
therapy after failure of csDMARDs experienced better drug
survival and better improvements in DAS28-ESR, SJC,
CDAI, and physical function than those who initiated TNFi.
Additional prospective randomized controlled trials may be
required to confirm these findings.
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